These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35422134)

  • 1. Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.
    Frånlund M; Månsson M; Godtman RA; Aus G; Holmberg E; Kollberg KS; Lodding P; Pihl CG; Stranne J; Lilja H; Hugosson J
    J Urol; 2022 Aug; 208(2):292-300. PubMed ID: 35422134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
    Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
    Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality.
    Hugosson J; Godtman RA; Carlsson SV; Aus G; Grenabo Bergdahl A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Scand J Urol; 2018 Feb; 52(1):27-37. PubMed ID: 29254399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality: 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial.
    Carlsson SV; Arnsrud Godtman R; Pihl CG; Vickers A; Lilja H; Hugosson J; Månsson M
    Eur Urol; 2023 Feb; 83(2):103-109. PubMed ID: 36334968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial.
    Hugosson J; Carlsson S; Aus G; Bergdahl S; Khatami A; Lodding P; Pihl CG; Stranne J; Holmberg E; Lilja H
    Lancet Oncol; 2010 Aug; 11(8):725-32. PubMed ID: 20598634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
    Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
    Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Association Between Age, Prostate Cancer Risk, and Higher Gleason Score in a Long-term Screening Program: Results from the Göteborg-1 Prostate Cancer Screening Trial.
    Godtman RA; Kollberg KS; Pihl CG; Månsson M; Hugosson J
    Eur Urol; 2022 Sep; 82(3):311-317. PubMed ID: 35120773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
    Pron G
    Ont Health Technol Assess Ser; 2015; 15(10):1-64. PubMed ID: 26366236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial.
    Frånlund M; Arnsrud Godtman R; Carlsson SV; Lilja H; Månsson M; Stranne J; Hugosson J
    Scand J Urol; 2018 Aug; 52(4):256-262. PubMed ID: 30241447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.
    Godtman RA; Carlsson S; Holmberg E; Stranne J; Hugosson J
    J Urol; 2016 May; 195(5):1390-1396. PubMed ID: 26678954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Family history in the Finnish Prostate Cancer Screening Trial.
    Saarimäki L; Tammela TL; Määttänen L; Taari K; Kujala PM; Raitanen J; Auvinen A
    Int J Cancer; 2015 May; 136(9):2172-7. PubMed ID: 25274038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up.
    Andriole GL; Crawford ED; Grubb RL; Buys SS; Chia D; Church TR; Fouad MN; Isaacs C; Kvale PA; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hsing AW; Izmirlian G; Pinsky PF; Kramer BS; Miller AB; Gohagan JK; Prorok PC;
    J Natl Cancer Inst; 2012 Jan; 104(2):125-32. PubMed ID: 22228146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Number of Screening Rounds and Postscreening Prostate Cancer Incidence: Results from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer Study.
    Pakarainen T; Raitanen J; Talala K; Taari K; Kujala P; Tammela TL; Auvinen A
    Eur Urol; 2016 Sep; 70(3):499-505. PubMed ID: 27210461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number of screening rounds attended and incidence of high-risk prostate cancer in the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC).
    Pakarainen T; Nevalainen J; Talala K; Taari K; Raitanen J; Kujala P; Stenman UH; Tammela TLJ; Auvinen A
    Cancer; 2021 Jan; 127(2):188-192. PubMed ID: 33048394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Prostatic-specific Antigen Threshold and Screening Interval in Prostate Cancer Screening Outcomes: Comparing the Swedish and Finnish European Randomised Study of Screening for Prostate Cancer Centres.
    Saarimäki L; Hugosson J; Tammela TL; Carlsson S; Talala K; Auvinen A
    Eur Urol Focus; 2019 Mar; 5(2):186-191. PubMed ID: 28803925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
    Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
    Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for prostate cancer.
    Ilic D; Neuberger MM; Djulbegovic M; Dahm P
    Cochrane Database Syst Rev; 2013 Jan; 2013(1):CD004720. PubMed ID: 23440794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.